News from the AI & ML world
DeeperML - #aihealthcare
|
Sam Khosroshahi@lambdalabs.com
//
References:
Fello AI
, MarkTechPost
NVIDIA is making significant strides in healthcare and robotics, leveraging the power of AI. A key development is the NVIDIA DNA LLM, designed to accelerate genomic research. This technology is set to transform how we analyze and interpret biological data, potentially leading to breakthroughs in curing diseases. NVIDIA is also working on new AI models, specifically multimodal models, to enhance physical common sense and embodied reasoning in AI systems, essential for applications like robotics.
NVIDIA's approach includes innovations like Evo 2, a large AI model for biology trained on a massive dataset of 9.3 trillion DNA base pairs, capable of not just analyzing but also generating entire genomic sequences. Furthermore, the introduction of Cosmos-Reason1, a vision-language model, aims to improve AI's ability to reason about physical environments, a critical advancement for robotics and self-driving vehicles. Dion Harris of NVIDIA provided context to Nvidia CEO Jensen Huang's GTC 2025 keynote, highlighting the company's focus on AI factories and advancements in simulation technology. Recommended read:
References :
Sam Khosroshahi@lambdalabs.com
//
References:
Fello AI
, lambdalabs.com
,
NVIDIA is pushing the boundaries of artificial intelligence in healthcare and robotics, introducing several groundbreaking advancements. One notable innovation is the DNA LLM, designed to decode the complex genetic information found in DNA, RNA, and proteins. This tool aims to transform genomic research, potentially leading to new understandings and treatments for various diseases.
The company's commitment to AI extends to robotics with the release of Isaac GR00T N1, an open-source platform for humanoid robots. This initiative is expected to accelerate innovation in the field, providing developers with the resources needed to create more advanced and capable robots. Additionally, an NVIDIA research team has developed Hymba, a family of small language models that combine transformer attention with state space models, surpassing the Llama-3.2-3B model in performance while significantly reducing cache size and increasing throughput. Recommended read:
References :
Neel Patel@AI & Machine Learning
//
References:
Compute
, IEEE Spectrum
Google Cloud and NVIDIA are collaborating to accelerate AI in healthcare by leveraging the NVIDIA BioNeMo framework and Google Kubernetes Engine (GKE). This partnership aims to speed up drug discovery and development by providing powerful infrastructure and tools for medical and pharmaceutical researchers. The NVIDIA BioNeMo platform is a generative AI framework enabling researchers to model and simulate biological sequences and structures, placing major demands for computing with powerful GPUs and scalable infrastructure.
With BioNeMo running on GKE, medical organizations can achieve breakthroughs and new research with levels of speed and effectiveness that were previously unheard of. Google DeepMind has also introduced Gemini Robotics, AI models built on Google's Gemini foundation model, enhancing robotics by integrating vision, language, and action. While AI isn't seen as a "silver bullet," Google DeepMind's Demis Hassabis emphasizes its undeniable benefits within five to ten years, as evidenced by developments like Alphafold 3, which accurately predicts the structure of molecules like DNA and RNA. Recommended read:
References :
@siliconangle.com
//
Eleos Health has secured $60 million in a Series C funding round, led by Greenfield Partners, to further develop its AI-powered behavioral health solutions. The funding will be used to expand its product offerings, grow its commercial team, and target underserved areas, including substance use disorder (SUD) treatment centers. This latest investment brings Eleos’ total funding to over $120 million, solidifying its position as a leader in the behavioral health AI space. Eleos utilizes AI agents to streamline clinical workflows, freeing up clinicians from administrative duties.
Eleos is also launching a new clinical documentation improvement product called Eleos Compliance, which leverages agentic AI to identify potential documentation errors before they result in penalties. This tool allows for near-instant review of submitted progress notes, streamlining appeals and improving accreditation efforts. Eleos has experienced rapid growth, tripling its annual revenue in each of its first three years and doubling it in 2024. The company’s technology aims to support clinicians by analyzing conversations to produce detailed notes and provide insights, while also improving patient engagement and care outcomes. Recommended read:
References :
|
BenchmarksBlogsResearch Tools |